Deferasirox

CHEMBL550348 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
373.4 g/mol
LogP
3.8
Phase
4

An oral iron chelator that binds excess iron in the body and promotes its excretion in the feces, used to treat chronic iron overload from blood transfusions in conditions like thalassemia and sickle cell disease. It is taken once daily as a dispersible tablet or film-coated tablet.

Peso Molecular

373,4000 g/mol

LogP

3,80

TPSA

108,00 Ų

Regra dos 5 de Lipinski

Aprovado

Áreas Terapêuticas

Mecanismo de Ação

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

O=C(O)c1ccc(-n2nc(-c3ccccc3O)nc2-c2ccccc2O)cc1

InChI

InChI=1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,25-26H,(H,27,28)

Molecular Formula

C21H15N3O4

HBD / HBA

3 / 6

Ligações Rotacionáveis

4

Átomos Pesados

28

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

An oral iron chelator that binds excess iron in the body and promotes its excretion in the feces, used to treat chronic iron overload from blood transfusions in conditions like thalassemia and sickle cell disease. It is taken once daily as a dispersible tablet or film-coated tablet.

Forms stable, water-soluble chelate complexes with specific metal ions, facilitating their excretion from the body through the kidneys. This reduces toxic metal burden in affected tissues.

Yes, Deferasirox is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL550348. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 214348. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.